Published in Biotech Business Week, January 22nd, 2007
The completed phase II study compared the safety and immunogenicity of Imvamune in 91 HIV infected subjects (CD4 > 350 cells/microl) to 60 healthy subjects. The study demonstrated that Imvamune is as equally well tolerated in HIV infected and healthy subjects.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.